Allozymes

Executive Summary

Allozymes is a Singapore-based enzyme engineering company that leverages proprietary ultra-high-throughput microfluidics, AI-driven data analytics, and scalable bioprocessing to discover and optimize enzymes for sustainable biosolutions. Founded in 2020, the company targets multiple sectors including pharmaceuticals, industrial biotechnology, food & nutrition, and diagnostics. Its platform enables rapid screening and engineering of enzymes with high specificity and efficiency, offering a greener alternative to traditional chemical processes. With a team of 10–50 employees, Allozymes is positioned as a platform-stage private company, focusing on serving as a technology enabler across industries. Allozymes differentiates itself through its integrated approach combining microfluidics, AI, and bioprocessing, which accelerates the development of custom enzymes for diverse applications. While still early-stage, the company has the potential to disrupt enzyme-driven manufacturing by reducing time and cost. Upcoming catalysts include progression to Series A or B funding, strategic partnerships with major chemical or pharmaceutical firms, and the commercial launch of its first proprietary enzyme product. The company’s emphasis on sustainability aligns with global trends, but execution risks remain given its limited public track record.

Upcoming Catalysts (preview)

• 2026Series A/B Funding Round60% success
• 2026Strategic Partnership with Pharma or Chemical Firm40% success
• 2027First Commercial Enzyme Product Launch30% success